The Procter Gamble Company

The Proctor 'gamble Company

Procter & Gamble Pharmaceuticals, Inc.

Marion David Francis

Frank Hallock Ebetino

Susan Mary Kaas

Lawrence Flora

Dennis G Nelson

Andrew John Tofe

John M Janusz

Irwin Y Rosenblum

Richard Allen Underwood

Kristine Hovancik

The present invention provides methods of treating a human or other animal subject afflicted with arthritis, including rheumatoid, arthritis and osteoarthritis, comprising a sixty (60)-day treatment period, comprised of an optional NSAID administration regimen and a phosphonate administration regimen, wherein

Methods for the treatment of arthritis using phosphonates and NSAIDS

The present invention relates to thio-substituted, nitrogen-containing heterocyclic phosphonate compounds, including bisphosphonates, phosphonoalkylphosphinates, phosphonocarboxylates, and phosphonosulfonates, and the pharmaceutically-acceptable salts and esters thereof useful for the treatment and prevention of osteoporosis and arthritis. These compounds have the general structure: ##STR1## (a) Z is a monocyclic or polycyclic heterocyclic ring moiety containing one or more heteroatoms selected from O, S, or N, at least one of which is N;

Thio-substituted, Nitrogen-containing, heterocyclic phosphonate

Compounds of the formula ##STR1## where m and n are integers 0 to 10 and m+n equals 0 to 10, (a) X is O or S

Sulfur-containing phosphonate compounds, pharmaceutical compositions,

The present invention relates to quaternary nitrogen-containing phosphate compounds, and the pharmaceutically-acceptable salts and esters thereof having the general structure: ##STR1## wherein: Z is a saturated, unsaturated, or aromatic, monocyclic or polycyclic carbocycle or monocyclic or polycyclic heterocycle containing one or more heteroatoms selected from O, S, or N;

Quaternary nitrogen-containing phosphonate compounds, pharmaceutical

The present invention relates to thio-substituted cyclic phosphonate compounds including bisphosphonates and phosphonoalkylphosphinates, and the pharmaceutically-acceptable salts and esters thereof. The present invention further relates to pharmaceutical compositions containing a safe and effective amount of a compound of the present invention, and pharmaceutically-acceptable excipients. Finally, the present invention relates to methods for treating or preventing pathological conditions characterized by abnormal calcium and phosphate metabolism in humans or other mammals including treating or preventing osteoporosis and arthritis, especially rheumatoid arthritis and osteoarthritis. The compounds may be monocyclic or bicyclic and have the following general structure: ##STR1## wherein (a) X and Y are independently selected from nil, O, S, and N;

Thio-substituted cyclic phosphonate compounds, pharmaceutical

Disclosed are quaternary nitrogen-containing, saturated or unsaturated monocyclic and bicyclic ring-containing bisphosphonate compounds, and pharmaceutically-acceptable salts and esters thereof. These compounds, which are useful for treating or preventing disorders of calcium and phosphate metabolism, have the following general structure: ##STR1## wherein (a) each X and Y are independently selected from nil, O, S, NR.sup.1 and N.sup.+ (R.sup.2).sub.2 ; if no R.sup.1 is N.sup.+ (R.sup.2).sub.2, then at least one of X or Y must be N.sup.+ (R.sup.2).sub.2 ;

Quaternary nitrogen containing phosphonate compounds, pharmaceutical

The subject invention encompasses methods and compositions comprising phosphate derivatives of triclosan for treating or preventing dental plaque, gingivitis or periodontal disease, of the oral cavity in humans or lower animals.

Oral care compositions comprising certain substituted diphenyl ethers

The present invention relates to quaternary nitrogen-containing phosphonate compounds, and the pharmaceutically-acceptable salts and esters thereof and having the general structure: ##STR1## wherein R.sup.1, R.sup.2, R.sup.5 and R.sup.8 are defined in claim 1, m and n are integers from 0 to 10; m+n is from 0 to 10;

Compositions for inhibiting the anomalous mobilization of calcium phosphates in animal tissue comprising an effective amount of certain phosphonate compounds as herein defined in combination with Vitamin D-like antirachitic compounds, and a method for treating or preventing conditions involving hard tissue demineralization in an animal comprising concurrently administering said phosphonates and Vitamin D-like antirachitic compounds to animals.

Compositions for inhibiting mobilization of calcium phosphate in animal

The anti-inflammatory activity of fenoprofen, ketoprofen, MK-830 and other phenylacetic acid-based anti-inflammatory drugs is enhanced by administration thereof in conjunction with a phosphonate compound such as EHDP or Cl.sub.2 MDP.

Phenylacetate anti-inflammatory composition

The anti-inflammatory activity of aspirin and other salicylate-based, anti-inflammatory drugs is enhanced by administration thereof in conjunction with a phosphonate compound such as EHDP or Cl.sub.2 MDP.

Salicylate anti-inflammatory composition

The anti-inflammatory activity of indomethacin, indoxole, and other indole-based drugs is enhanced by administration thereof in conjunction with a phosphonate compound such as EHDP or Cl.sub.2 MDP.

Indole anti-inflammatory composition

The anti-inflammatory activity of ibuprofen, ibufenac and other p-(isobutylphenyl)acetic acid-based anti-inflammatory drugs is enhanced by adminstration thereof in conjuction with a phosphonate compound such as EHDP or Cl.sub.2 MDP.

Isobutylphenylacetate anti-inflammatory composition

Technetium-99m has ideal characteristics for imaging the upper and lower GI tract and determining stomach emptying and intestinal transit time when used with an insoluble particulate material. For example, crystalline and amorphous calcium phosphate particles can be effectively labeled in a one-step process using .sup.99m TcO.sub.4 and SnCl.sub.2. These labeled particles have insignificant mass and when administered orally pass through the GI tract unchanged, without affecting the handling and density of the intestinal contents. Visualization of the esophageal entry into the stomach, the greater and lesser curvatures of the stomach, ejection into the duodenum, and rates of passage through the upper and lower GI tract are obtained. The slurry of .sup.99m Tc particulate can be given rectally by enema. Good images of the cecum and the ascending, transverse, and descending colon are obtained. Mucosa folds and the splenic and hepatic flexures are visualized. The resilience of the large intestine is also readily visualized by pneumocolonographic techniques.

Gastrointestinal scanning agent

A composition and method for the preparation of a technetium-99 m based scintigraphic scanning agent are disclosed. The agent is prepared by the addition of a pertechnetate-99 m solution to an anhydrous salt composition comprising a phosphonic acid or a pharmaceutically acceptable salt thereof and a non-toxic, water-soluble, anhydrous, stannous, ferrous or chromous salt of hydrochloric or sulfuric acid.

Growing community of inventors

Cincinnati, OH, United States of America

Marion David Francis